Compare Alcon AG (ALC) vs JD.Com Inc (JD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs JD.Com Inc — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while JD.Com Inc trades at $27.62 (market cap $36.37B). The key difference: Alcon AG and JD.Com Inc are close in size by market cap, and JD.Com Inc pays the higher dividend (3.78%). Which is the better fit depends on your goals.
| ALC | JD | |
|---|---|---|
Market Cap | $32.69B | $36.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $36.17 |
52-Week Low | $62.02 | $25.19 |
Enterprise Value | $36.28B | $22.53B |
Dividend Yield | 0.54% | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
JD trades at $26.49, down 0.49% on the day, with a bearish technical signal and mixed sentiment. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 show operational strength, but net income margin compression to 1.05% in 2025 raises concerns. The stock appears undervalued with a P/S of 0.2 and P/E of 19.66, while analyst consensus remains strongly bullish with a $39.20 price target.
The outlook is cautiously optimistic given JD's low valuation and consistent earnings outperformance, but risks include legal investigations, margin pressure, and macroeconomic headwinds. Upside potential exists if the company can sustain revenue growth and improve profitability, though near-term volatility may persist due to negative news flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
